Biogen Inc (BIIB)
Official siteHEALTHCARE • DRUG MANUFACTURERS - GENERAL • NASDAQ
Market Cap: $37.20B
Last updated: Nov 17, 2026 at 4:15 PM ET
Biogen Inc (BIIB) Statistics
Biogen (BIIB) has a market cap of $37.20B and an enterprise value of $43.59B. Its return on invested capital of 1.27% compares with a 7.58% median across 10 similar companies. Its trailing P/E of 21.3x is above its 10-year median of 12.4x.
Total Valuation
Enterprise value is 17.17% above the market cap, as debt exceeds cash.
| Market Cap | $37.20B |
|---|---|
| Enterprise Value | $43.59B |
| Latest price (Nov 17, 2026) | $250.79 |
Key Dates
The next earnings report is expected on Feb 4, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 4, 2027 (expected) |
|---|---|
| Last Earnings Date | Oct 28, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 3.6x and 2.0x. Its year-end P/E ranged from 7.5x to 17.2x from 2016 to 2025.
| P/E Ratio | 21.3x |
|---|---|
| Forward P/E | 19.6x |
| P/S Ratio | 3.6x |
| Forward P/S | 3.5x |
| P/B Ratio | 2.0x |
| P/FCF Ratio | 17.9x |
| P/OCF Ratio | 16.6x |
| PEG Ratio | 2.9 |
Enterprise Valuation
Counting debt and cash, the company is valued at 22.9x EBITDA and 21.0x free cash flow.
| EV / Earnings | 130.4x |
|---|---|
| EV / Sales | 4.2x |
| EV / EBITDA | 22.9x |
| EV / FCF | 21.0x |
Price Statistics
The stock is up 49.68% over 52 weeks and trades 6.84% above its 50-day average.
| Beta (1Y) | 0.39 |
|---|---|
| 52-Week Change | +49.68% |
| 1-Month Change | +7.41% |
| 3-Month Change | +13.19% |
| 6-Month Change | +31.61% |
| 5-Year Change | -4.90% |
| 10-Year Change | -9.48% |
| Total Return (1Y) | +49.68% |
| Total Return (3Y CAGR) | +3.23% |
| Total Return (5Y CAGR) | -0.47% |
| Return vs SPY (1Y) | +36.99% |
| Max Drawdown (1Y) | -14.34% |
| Max Drawdown (3Y) | -57.65% |
| Sharpe Ratio (1Y) | 1.17 |
| Correlation with SPY (1Y) | 0.16 |
| 50-Day Average | $234.73 |
| 200-Day Average | $205.87 |
| 52-Week Range | $160.36 to $261.00 |
| RSI (14 Days) | 56.0 |
| Average Volume (20 Days) | 1.20M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 1.95x current liabilities, and total debt is 0.41x shareholder equity.
| Current Ratio | 1.95x |
|---|---|
| Quick Ratio | 1.37x |
| Debt / Equity | 0.41x |
| Debt / EBITDA | 4.06x |
| Debt / FCF | 3.71x |
Returns and Efficiency
Return on invested capital is 1.27% over the last 12 months, against a 5-year average of 8.41%.
| Return on Equity (ROE) | 1.77% |
|---|---|
| Return on Assets (ROA) | 1.04% |
| Return on Invested Capital (ROIC) | 1.27% |
| ROE (5Y Average) | 12.53% |
| ROA (5Y Average) | 6.77% |
| ROIC (5Y Average) | 8.41% |
| Asset Turnover | 0.34x |
| Inventory Turnover | 1.16x |
| Receivables Turnover | 4.31x |
| Cash Conversion Cycle | 342 days |
Taxes
Income tax took 21.93% of pretax income over the last 12 months.
| Income Tax (TTM) | $97.60M |
|---|---|
| Effective Tax Rate | 21.93% |
Scores
BIIB has an Altman Z-Score of 3.11, in the safe zone above 2.99, and a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 3.11 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 4 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $10.30B over the last 12 months is up 2.30% from the 12 months before.
| Revenue | $10.30B |
|---|---|
| Revenue Growth (YoY) | +2.30% |
| Gross Profit | $7.62B |
| Operating Income | $431.90M |
| Pretax Income | $445.10M |
| Net Income | $334.30M |
| EBITDA | $1.90B |
| Reported EPS (TTM) | $11.78 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 59.03% of the $32.05B in total assets.
| Cash and Equivalents | $1.30B |
|---|---|
| Total Debt | $7.69B |
| Net Debt | $6.39B |
| Net Debt Per Share | $43.22 |
| Working Capital | $3.69B |
| Shareholder Equity | $18.92B |
| Book Value Per Share | $128.03 |
| Tangible Book Value | -$1.45B |
| Total Assets | $32.05B |
| Total Liabilities | $13.13B |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $176.40M of capital spending, operating cash flow left $2.07B of free cash flow.
| Operating Cash Flow | $2.25B |
|---|---|
| Capital Expenditures | $176.40M |
| Free Cash Flow | $2.07B |
| FCF Per Share | $14.01 |
| Depreciation and Amortization | $1.46B |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 4.19%, against a 5-year average of 21.75%.
| Gross Margin | 73.96% |
|---|---|
| Operating Margin | 4.19% |
| Pretax Margin | 4.32% |
| Net Margin | 3.25% |
| EBITDA Margin | 18.42% |
| FCF Margin | 20.11% |
| Gross Margin (5Y Average) | 76.89% |
| Operating Margin (5Y Average) | 21.75% |
| Net Margin (5Y Average) | 17.32% |
Growth
Revenue fell 0.94% a year over 3 years, and EPS 4.74% a year.
| Revenue Growth (3Y CAGR) | -0.94% |
|---|---|
| Revenue Growth (5Y CAGR) | -5.96% |
| EPS Growth (3Y CAGR) | -4.74% |
| EPS Growth (5Y CAGR) | -14.17% |
| FCF Growth (3Y CAGR) | +21.48% |
| FCF Growth (5Y CAGR) | -11.63% |
| Operating Income Growth (3Y CAGR) | -23.55% |
| Book Value Per Share Growth (2Y CAGR) | +10.69% |
| Tangible Book Per Share Growth (2Y CAGR) | +243.95% |
Dividends and Yields
BIIB does not pay a dividend. Its free cash flow yield is 5.59%.
| Earnings Yield | 4.69% |
|---|---|
| FCF Yield | 5.59% |
| Shareholder Yield | 0.00% |
Stock Splits
The last split was a 3-for-1 forward split on Jan 18, 2001.
| Last Split Date | Jan 18, 2001 |
|---|---|
| Split Type | Forward split |
| Split Ratio | 3:1 |
Peer Position
Against 8 similar companies, BIIB has the 3rd highest P/E.
P/E RatioPeer median 14.4x
P/S RatioPeer median 4.0x
ROICPeer median 7.58%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +6.54%
| P/E Ratio | 21.3x vs 14.4x median |
|---|---|
| P/S Ratio | 3.6x vs 4.0x median |
| ROIC | 1.27% vs 7.58% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +2.30% vs +6.54% median |
Analyst Forecast
Consensus estimates put revenue growth at 4.38% and EPS growth at 3.12% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +4.38% |
|---|---|
| EPS Growth Forecast (2Y CAGR) | +3.12% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About BIIB
What is BIIB's market cap?
Biogen has a market cap of $37.20B. Its enterprise value, which adds debt and subtracts cash, is $43.59B.
What is BIIB's P/E ratio?
Biogen has a trailing P/E ratio of 21.3x and a forward P/E of 19.6x.
How many shares of BIIB are outstanding?
Biogen has 147.80M shares outstanding. The count is up 0.82% from a year earlier.
Does BIIB pay a dividend?
No. Biogen does not pay a dividend.
How much debt does BIIB have?
Biogen has $7.69B of total debt and $1.30B of cash and equivalents, a net debt position of $6.39B.
BIIB pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors